Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells

Imatinib Mesylate (IM) and other tyrosine kinase inhibitor (TKI) therapies have had a major impact on the treatment of chronic myeloid leukemia (CML). However, TKI monotherapy is not curative, with relapse and persistence of leukemic stem cells (LSCs) remaining a challenge. We have recently identifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hanyang, Chen, Min, Rothe, Katharina, Lorenzi, Matthew V., Woolfson, Adrian, Jiang, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226710/
https://www.ncbi.nlm.nih.gov/pubmed/25226617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226710/
https://www.ncbi.nlm.nih.gov/pubmed/25226617

Ejemplares similares